共 50 条
Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy
被引:3
|作者:
McFaline-Figueroa, Jose L.
[1
,2
]
Srivatsan, Sanjay
[2
,3
]
Hill, Andrew J.
[2
]
Gasperini, Molly
[2
]
Jackson, Dana L.
[2
]
Saunders, Lauren
[2
]
Domcke, Silvia
[2
]
Regalado, Samuel G.
[2
]
Lazarchuck, Paul
[4
]
Alvarez, Sarai
[2
]
Monnat Jr, Raymond J.
[2
,4
,5
]
Shendure, Jay
[2
,5
,6
,7
,8
]
Trapnell, Cole
[2
,5
,6
,8
]
机构:
[1] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA
[2] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
[3] Univ Washington, Med Scientist Training Program, Seattle, WA USA
[4] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA
[5] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA
[6] Allen Discovery Ctr Cell Lineage Tracing, Seattle, WA 98109 USA
[7] Univ Washington, Howard Hughes Med Inst, Seattle, WA USA
[8] Brotman Baty Inst Precis Med, Seattle, WA 98195 USA
来源:
关键词:
MISMATCH REPAIR;
MEK INHIBITION;
ACQUIRED-RESISTANCE;
STEM-CELLS;
P-TEFB;
CANCER;
GENE;
EXPRESSION;
TRANSCRIPTION;
MUTATIONS;
D O I:
10.1016/j.xgen.2023.100487
中图分类号:
Q2 [细胞生物学];
学科分类号:
071009 ;
090102 ;
摘要:
Chemical genetic screens are a powerful tool for exploring how cancer cells' response to drugs is shaped by their mutations, yet they lack a molecular view of the contribution of individual genes to the response to exposure. Here, we present sci-Plex-Gene-by-Environment (sci-Plex-GxE), a platform for combined single -cell genetic and chemical screening at scale. We highlight the advantages of large-scale, unbiased screening by defining the contribution of each of 522 human kinases to the response of glioblastoma to different drugs designed to abrogate signaling from the receptor tyrosine kinase pathway. In total, we probed 14,121 geneby -environment combinations across 1,052,205 single -cell transcriptomes. We identify an expression signature characteristic of compensatory adaptive signaling regulated in a MEK/MAPK-dependent manner. Further analyses aimed at preventing adaptation revealed promising combination therapies, including dual MEK and CDC7/CDK9 or nuclear factor KB (NF -KB) inhibitors, as potent means of preventing transcriptional adaptation of glioblastoma to targeted therapy.
引用
收藏
页数:26
相关论文